Metabolic Pathway of Osilodrostat in Equine Urine Established through High-resolution Mass Spectrometric Characterization for Doping Control
- 1 September 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 25 (7) , 489-504
Abstract
Objective: Osilodrostat, used to treat Cushing's disease, exhibits an anabolic effect, leading to its classification as a prohibited substance in horseracing and equestrian sports. This study reports the characterization of osilodrostat metabolites in horse urine and elucidates its metabolic pathways for the first time for doping control purposes. Methods: Osilodrostat was administered nasoesophageally to four thoroughbreds (one gelding and three mares) at a dose of 50 mg each. Potential metabolites were extensively screened via our developed generic approach employing differential analysis to identify metabolites. Specifically, high-resolution mass spectral data were compared between pre- and post-administration samples on the basis of criteria of fold-changes of peak areas and their P values. Potential metabolite candidates were further identified through mass spectral interpretations using product ion scan data. Results: A total of 37 metabolites were identified after comprehensive analysis. Osilodrostat was predominantly metabolized into a mono-hydroxylated form M1c (~40%) alongside osilodrostat glucuronide M2 (~17%). Given their longest detection time (2 weeks after administration) and the identification of several conjugates of osilodrostat and M1c, including a novel conjugate of riburonic acid, we recommend monitoring both osilodrostat and M1c after hydrolysis during the screening stage. However, only osilodrostat can be used for confirmation because of the availability of a reference material. Conclusion: It is advisable to screen for both osilodrostat and its mono-hydroxylated metabolite M1c to effectively monitor horse urine for the potential misuse or abuse of osilodrostat. For suspicious samples, confirmation of osilodrostat using its reference material is required.Keywords
This publication has 45 references indexed in Scilit:
- A fully automated method to quantitate total carbon dioxide in equine plasma by headspace GCMSDrug Testing and Analysis, 2022
- Metabolic study of hypoxia‐inducible factor stabilizers BAY 87‐2243, MK‐8617, and PT‐2385 in equine liver microsomes for doping controlDrug Testing and Analysis, 2022
- A quantitative method for the simultaneous detection of SR9009 and SR9011 in equine plasma using liquid chromatography–electrospray ionization–tandem mass spectrometryDrug Testing and Analysis, 2022
- Long‐term monitoring of IOX4 in horse hair and its longitudinal distribution with segmental analysis using liquid chromatography/electrospray ionization Q Exactive high‐resolution mass spectrometry for the purpose of doping controlDrug Testing and Analysis, 2022
- Identification of potential biomarkers in urine and plasma after consumption of tobacco product in horsesDrug Testing and Analysis, 2022
- Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high‐resolution mass spectrometer for the purpose of doping controlDrug Testing and Analysis, 2021
- Intelligence‐based anti‐doping from an equine biological passportDrug Testing and Analysis, 2017
- Interlaboratory trial for the measurement of total cobalt in equine urine and plasma by ICP‐MSDrug Testing and Analysis, 2017
- Identification of gonadotropin‐releasing hormone metabolites in greyhound urineDrug Testing and Analysis, 2017
- Drug metabolism in the horse: a reviewDrug Testing and Analysis, 2010